Why Alnylam Pharmaceuticals Stock Slipped Today
Investors weren't in a very forgiving mood with commercial-stage biotech Alnylam Pharmaceuticals (NASDAQ: ALNY). After the company reported its latest set of quarterly results, those folks showed their displeasure by trading the stock down by more than 4% that trading session.
Alnylam took the wraps off its fourth-quarter and full-year 2025 results before market open. These revealed that the company's revenue nearly doubled on a year-over-year basis, landing at just under $1.1 billion.
Image source: Getty Images.
Source Fool.com
